A retrospective study of Brentuximab-vedotin-ICE in patients with relapsed/refractory Hodgkin's lymphoma
Latest Information Update: 10 Oct 2022
At a glance
- Drugs Brentuximab vedotin (Primary) ; Carboplatin; Etoposide; Granulocyte colony-stimulating factors; Ifosfamide; Mesna
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 10 Oct 2022 New trial record
- 01 Oct 2022 Results published in the Clinical Lymphoma, Myeloma & Leukemia